Drug intelligence / Profile preview

GT601

Development stage: Unknown
Lead developer: Grit Biotechnology
Modality: Vaccines & Immunotherapeutics

Overview

GT601 is a next-generation neoantigen cancer vaccine designed for hepatocellular carcinoma (HCC), leveraging AI-based neoantigen prediction combined with antigen-presenting cell (APC)-targeted delivery to enhance antitumor immune responses. Developed by Grit Biotechnology (Zhuhai Grit Biotechnology), it represents a first-in-class personalized immunotherapy approach that stimulates T-cell activation against patient-specific tumor neoantigens, aiming to overcome limitations of traditional vaccines by improving antigen presentation and immune potency in the tumor microenvironment.[7][12][13][14]

Beyond the preview

Go deeper on GT601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT601.

Explore the full profile